FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4286295073> ?p ?o ?g. }

• W4286295073 endingPage "11519" @default.
• W4286295073 startingPage "11519" @default.
• W4286295073 abstract "11519 Background: Pegylated liposomal doxorubicin (PLD) was found to have improved toxicity profile, especially with regards to reduced cardiotoxicity. The objectives of this study were to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of PLD in combination with cyclophosphamide and vincristine (PCV regimen) and describe the toxicities and response of this regimen. Methods: This was an open-label, single-center, single-arm phase I study utilizing a “3 + 3” design. The primary endpoint was the MTD of PLD, and the secondary endpoints included safety, objective response rate (ORR), disease control rate (DCR), and progression-free survival (PFS). Efficacy was evaluated using RECIST 1.1. PFS was defined as the time from treatment until disease progression or death. This study included cohort A and cohort B. Three dose levels were studied in cohort A, PLD 30 mg/m 2 (L1), 40 mg/m 2 (L2) or 50 mg/m 2 (L3) d1 + cyclophosphamide and mesna at 1 g/m 2 /d d1-2 + vincristine 1.5 mg/m 2 /d (≯2mg) d1 every 3 weeks. As the endpoint of the study could not be reached, we changed the dose of cyclophosphamide and mesna to 1.5 g/m 2 /d d1 in cohort B. Results: Eleven in cohort A and 34 in cohort B were enrolled, the median age was 6 years (range 1-15). Forty-three patients were eligible and evaluable for toxicity, and 35 (77.8%) patients were evaluable for response. Diagnoses were rhabdomyosarcoma (n = 29, 64.4%), Ewing's sarcoma (n = 4), and others. The median number of prior regimens was 2 (range 1-5). The most common adverse event (AE) was grade 3 or grade 4 neutropenia with a proportion of 90.9% and 65.5% in cohort A and cohort B, respectively. There was no significant difference in ORR (60% vs. 48%) and DCR (90% vs. 88%) between the two cohorts. The ORR (60% vs. 0, P = 0.019) and DCR (96.7% vs. 40%, P = 0.006) were significantly higher in Group 1 (rhabdomyosarcoma, Ewing's sarcoma, Wilm's tumor, fibrosarcoma, undifferentiated sarcoma) compared with Group 2 (neuroblastoma, osteosarcoma, embryonal sarcoma, epithelioid sarcoma, extrarenal rhabdoid tumor). The 12-month PFS of Group 1 was also better than Group 2 (79% vs. 60%, P = 0.041). Conclusions: The PCV regimen demonstrated an acceptable toxicity profile and promising clinical efficacy in pediatric patients with R/R rhabdomyosarcoma, Ewing's sarcoma, Wilm's tumor, fibrosarcoma, and undifferentiated sarcoma. Increasing the dose of cyclophosphamide did not improve the efficacy, but increased the toxicity. The RP2D for future studies is PLD 30 mg/m 2 /d for one day. Clinical trial information: NCT04213612. [Table: see text]" @default.
• W4286295073 created "2022-07-21" @default.
• W4286295073 creator A5004735532 @default.
• W4286295073 creator A5008841145 @default.
• W4286295073 creator A5016619271 @default.
• W4286295073 creator A5018892762 @default.
• W4286295073 creator A5019348955 @default.
• W4286295073 creator A5025137178 @default.
• W4286295073 creator A5036663316 @default.
• W4286295073 creator A5047365731 @default.
• W4286295073 creator A5065859286 @default.
• W4286295073 date "2022-06-01" @default.
• W4286295073 modified "2023-09-30" @default.
• W4286295073 title "Phase I study of pegylated liposomal doxorubicin in combination with cyclophosphamide and vincristine in pediatric patients with relapsed/refractory sarcoma and other malignant solid tumors." @default.
• W4286295073 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.11519" @default.
• W4286295073 hasPublicationYear "2022" @default.
• W4286295073 type Work @default.
• W4286295073 citedByCount "0" @default.
• W4286295073 crossrefType "journal-article" @default.
• W4286295073 hasAuthorship W4286295073A5004735532 @default.
• W4286295073 hasAuthorship W4286295073A5008841145 @default.
• W4286295073 hasAuthorship W4286295073A5016619271 @default.
• W4286295073 hasAuthorship W4286295073A5018892762 @default.
• W4286295073 hasAuthorship W4286295073A5019348955 @default.
• W4286295073 hasAuthorship W4286295073A5025137178 @default.
• W4286295073 hasAuthorship W4286295073A5036663316 @default.
• W4286295073 hasAuthorship W4286295073A5047365731 @default.
• W4286295073 hasAuthorship W4286295073A5065859286 @default.
• W4286295073 hasConcept C126322002 @default.
• W4286295073 hasConcept C141071460 @default.
• W4286295073 hasConcept C143998085 @default.
• W4286295073 hasConcept C203092338 @default.
• W4286295073 hasConcept C2776694085 @default.
• W4286295073 hasConcept C2776755627 @default.
• W4286295073 hasConcept C2777506904 @default.
• W4286295073 hasConcept C2778239845 @default.
• W4286295073 hasConcept C2779429289 @default.
• W4286295073 hasConcept C2780376820 @default.
• W4286295073 hasConcept C2781413609 @default.
• W4286295073 hasConcept C535046627 @default.
• W4286295073 hasConcept C71924100 @default.
• W4286295073 hasConcept C72563966 @default.
• W4286295073 hasConceptScore W4286295073C126322002 @default.
• W4286295073 hasConceptScore W4286295073C141071460 @default.
• W4286295073 hasConceptScore W4286295073C143998085 @default.
• W4286295073 hasConceptScore W4286295073C203092338 @default.
• W4286295073 hasConceptScore W4286295073C2776694085 @default.
• W4286295073 hasConceptScore W4286295073C2776755627 @default.
• W4286295073 hasConceptScore W4286295073C2777506904 @default.
• W4286295073 hasConceptScore W4286295073C2778239845 @default.
• W4286295073 hasConceptScore W4286295073C2779429289 @default.
• W4286295073 hasConceptScore W4286295073C2780376820 @default.
• W4286295073 hasConceptScore W4286295073C2781413609 @default.
• W4286295073 hasConceptScore W4286295073C535046627 @default.
• W4286295073 hasConceptScore W4286295073C71924100 @default.
• W4286295073 hasConceptScore W4286295073C72563966 @default.
• W4286295073 hasIssue "16_suppl" @default.
• W4286295073 hasLocation W42862950731 @default.
• W4286295073 hasOpenAccess W4286295073 @default.
• W4286295073 hasPrimaryLocation W42862950731 @default.
• W4286295073 hasRelatedWork W1499275448 @default.
• W4286295073 hasRelatedWork W2016341751 @default.
• W4286295073 hasRelatedWork W2042515268 @default.
• W4286295073 hasRelatedWork W2121694206 @default.
• W4286295073 hasRelatedWork W2370952297 @default.
• W4286295073 hasRelatedWork W2385309123 @default.
• W4286295073 hasRelatedWork W2403217642 @default.
• W4286295073 hasRelatedWork W2403331838 @default.
• W4286295073 hasRelatedWork W2406181293 @default.
• W4286295073 hasRelatedWork W2410654427 @default.
• W4286295073 hasVolume "40" @default.
• W4286295073 isParatext "false" @default.
• W4286295073 isRetracted "false" @default.
• W4286295073 workType "article" @default.